Ikonisys announces the successful installation of the Ikoniscope20 at TomaLab, one of the largest genetics laboratories in Italy

  • Future applications for new assays are being evaluated to further exploit the instrument’s capabilities to automate laboratory workflow and analyze samples otherwise impossible to study manually.

PARIS, February 07, 2022–(BUSINESS WIRE)–Regulatory news:

Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO), a company specializing in the early and accurate detection of cancer with a unique fully automated solution for medical diagnostic laboratories, announced the successful sale and installation of the Ikoniscope20 at Toma Advanced Biomedical Assays Spa (Busto Arsizio, VA , Italy) and the continuation of the fruitful collaboration between the laboratory and the company. Since installation, TomaLab has successfully validated the Ikoniscope20 for routine FISH testing in oncology, using multiple applications ranging from lung cancer (oncoFISH ALK) to bladder cancer (bladder oncoFISH).

This partnership is a concrete step in the marketing strategy and demonstrates the ability of the commercial organization to achieve the objective of rapid growth of Ikoniscope20 installations: TomaLab will serve as a reference laboratory for Ikonisys, allowing interested stakeholders and prospects to review the instrument and its capabilities.

The laboratory will continue to collaborate in the development of new applications for tests that are or will become of particular interest in the field of cancer diagnosis, with particular emphasis on the capabilities of the instrument to perform both tests based on FISH and on antibodies. trials. This is a factual step in the strategy mentioned at the IPO to develop new applications, expanding into promising new segments of the IVD market.

Dr. Tshering Dorji, Head of Pathology, TomaLabcommented, “We are very impressed with the Ikoniscope20 and excited to continue our collaboration with Ikonisys. The compact size of the instrument allowed us to fit it perfectly into our setup and the high throughput of this new FISH analyzer is very impressive. to the high quality of the scanned images reported and the easy-to-use remote connection, the instrument continues to play a very important role in our daily patient care workflow.”

Michael Kilpatrick, scientific director of Ikonisys, added “We are honored and delighted to continue to work with a leading European laboratory such as TomaLab. This, in our opinion, certifies the hard work that has been put into the development of the new instrument in order to meet and exceed the expectations of the The collaboration with TomaLab has already allowed us to develop new applications in the past and we look forward to the great ideas that may arise from the discussion with such a sophisticated customer, to expand our product portfolio in FISH and other In the short term, this will allow us to add new applications for the detection of genetic aberrations in multiple tissue types, while continuing to use the capabilities of the platform to develop tests based on the combined analysis of genes and proteins.

Jurgen Schipper, Commercial Director of Ikonisys concluded: “Having TomaLab act as the first reference laboratory for us is a great support as we continue our expansion into the European market. After the recent hiring of our experienced commercial director for France, this is another important building block in building our sales strategy, based on initial sales to key opinion leaders and highly respected customers, who will act as sponsors for our innovative instrument and applications.”

About Ikonisys

Ikonisys SA is a cell diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specializing in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully automated solution designed to provide accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. With its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on circulating tumor cells (CTCs).

For more information, visit www.Ikonisys.com


This press release contains forward-looking statements about the prospects and development of the Company. These statements are sometimes identified by the use of the future, conditional and forward-looking words such as “believe”, “aim”, “expect”, “intend”, “estimate”, “believe”. “, “should”, “could”, “will” or “will” or, where applicable, the negative form of these terms or any other variation or similar expression. This information is not historical data and should not be interpreted as a guarantee that the facts and data stated will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or change due to uncertainties related to the environment economic, financial, competitive and regulatory This information contains data relating to the intentions, estimates and objectives of the Company concerning in particular the market, strategy, growth, results, financial situation and Company cash. The forward-looking information contained in this press release speaks only as of the date of this press release. The Company does not undertake to update the forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all the risks, uncertainties or other factors that could affect its business, their potential impact on its business or the extent to which the materialization of a risk or of a combination of risks could cause the results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220207005776/en/


Alessandro Mauri
[email protected]

Olivier Bricaud / Louis Victor Delouvrier
Investor Relations
[email protected]
Phone. : +33 (0)1 44 71 94 92

Nicolas Merigeau
Media Relations
[email protected]
Phone. : +33 (0)1 44 71 94 98

Comments are closed.